Factors predictive of visual acuity outcomes 1 year after photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy

Retina

Volumn 31, Issue 5, 2011, Pages 857-865

  Hikichi, Taiichi ^a   Ohtsuka, Hideo ^a   Higuchi, Makoto ^a   Matsushita, Takuro ^a   Ariga, Hiroko ^a   Kosaka, Shoko ^a   Matsushita, Reiko ^a   Takami, Kimitaka ^a  

^a Ohtsuka Eye Hospital   (Japan)

Author keywords

Photodynamic therapy; polypoidal choroidal vasculopathy

Indexed keywords

VERTEPORFIN;

AGED; ARTICLE; FEMALE; FOLLOW UP; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PREDICTION; PROSPECTIVE STUDY; RETINA DETACHMENT; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHOROID; CHOROID DISEASES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PHOTOCHEMOTHERAPY; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 79955554660     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181fecda9     Document Type: Article

References (34)

1. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990;10: 1-8. (Pubitemid 20201879)
2. Stern RM, Zalov ZN, Zegarra H, Gutman FA. Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. Am J Ophthalmol 1985;100: 560-569. (Pubitemid 16206988)
3. Kleiner RC, Brucker AJ, Johnston RL. The posterior uveal bleeding syndrome. Retina 1990;10:9-17. (Pubitemid 20201880)
4. Perkovich BT, Zakov ZN, Berlin LA,Weidenthal D. An update on multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. Retina 1990;10:18-26. (Pubitemid 20201881)
5. Spaide RF, Yannuzzi LA, Slakter JS, Jorenson J. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 1995;15:100-110.
6. Uyama M, Matsubara T, Fukushima, et al. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol 1999;117:1035-1042. (Pubitemid 29372936)
7. Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002;133: 639-648. (Pubitemid 34462012)
8. Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy. Incidence, demographic features, and clinical characteristics. Arch Ophthalmol 2003;121:1392-1396. (Pubitemid 37243739)
9. Chan WM, Lam DS, Lai TYY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. one-year results of a prospective case series. Ophthalmology 2004;111:1576-1584. (Pubitemid 39030815)
10. Saito M, Iida T, Nagayama D. Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 2008; 92:1642-1647.
11. Spaide RF, Donsoff I, Lam DL, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 2002;22:529-535. (Pubitemid 35176066)
12. Quaranta M, Maget-Faysse M, Coscas G. Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Am J Ophthalmol 2002;134: 277-280. (Pubitemid 34831840)
13. Lee SC, Seong YS, Kim SS, Koh HJ, Kwon OW. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula. Ophthalmologica 2004;218:193-201. (Pubitemid 38596586)
14. Silva RM, Figueria J, Cachulo ML, et al. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 2005;243:973-979. (Pubitemid 41631036)
15. Otani A, Sasahara M, Yodoi Y, et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007;144:7-14.
16. Eandi CM, Ober MD, Freund KB, Slakter JS, Yannuzzi LA. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. Retina 2007;27:825-831. (Pubitemid 47479375)
17. Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 2008;28:717-722. (Pubitemid 351655124)
18. Kurashige Y, Otani A, Sasahara M, et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2008;146:513-519.
19. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008;115:141-146. (Pubitemid 350309415)
20. Tsuchiya D, Yamamoto T, Kawasaki R, Yamashita H. Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina 2009;29:960-965.
21. Tamura H, Tsujikawa A, Otani A, et al. Polypoidal choroidal vasculopathy appearing as classic choroidal neovascularization on fluorescein angiography. Br J Ophthalmol 2007;91: 1152-1159. (Pubitemid 47344888)
22. Hirami Y, Tsujikawa A, Otani A, et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2007;27:335-341. (Pubitemid 46398898)
23. Wakabayashi T, Gomi F, Tsujikawa M, Tano Y. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 2008;92:936-940. (Pubitemid 351969674)
24. LeeMW, Yeo I,Wong D, Ang CL. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy. Eye 2009; 23:1417-1422.
25. Honda S, Imai H, Yamashita K, et al. Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan. Ophthalmologica 2009;223:333-338.
26. Costa RA, Calucci D, Skaf M, et al. Optical coherence tomography 3: automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci 2004;45:2399-2406. (Pubitemid 38902615)
27. Japanese Study Group of Polypoidal Choroidal Vasculopathy. Criteria for diagnosis of polypoidal choroidal vasculopathy [in Japanese]. Nippon Ganka Gakkai Zasshi 2005;109: 417-427.
28. Maruko I, Iida T, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144:15-22.
29. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 1999;117:1329-1345.
30. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991;109:1242-1257.
31. Gomi F, Sawa H, Tsujikawa M, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:70-73.
32. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month report results. Br J Ophthalmol 2010;94: 297-301.
33. Lai TY, Chan WM, Liu DT, Luk FO, Lan DS. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:661-666. (Pubitemid 351684177)
34. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, et al. Short-term anatomic and effect of ranibizumab for polypoidal choroidal vasculopathy. Eur J Ophthalmol 2008;18: 645-648.